Company Encyclopedia
View More
name
Capricor Therap
CAPR.US
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD.
1.902 T
CAPR.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking209/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-107.79%E
    • Profit Margin-736.62%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-52.08%E
    • Net Profit YoY-140.35%E
    • Total Assets YoY36.03%A
    • Net Assets YoY22.86%A
  • Cash ScoreE
    • Cash Flow Margin-13.58%D
    • OCF YoY-52.08%E
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreB
    • Gearing Ratio33.67%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    How Investors May Respond To Capricor Therapeutics (CAPR) Phase 3 HOPE-3 Success And $150 Million Equity Raise

    Capricor Therapeutics completed a $150 million public offering after positive Phase 3 HOPE-3 results for Deramiocel in Duchenne muscular dystrophy. This funding supports Deramiocel's development and potential commercialization. The investment narrative hinges on regulatory approval, with the recent data as a key catalyst. However, regulatory unpredictability remains a risk. Capricor projects $134.4 million revenue and $14.4 million earnings by 2028, requiring significant growth. Fair value estimates vary widely, reflecting differing views on Capricor's potential.

    Simplywall·
    US
    CAPR
    -4.27%
    Simplywall·
    US
    CAPR
    -4.27%

    Trending | CAPR Decreases 4% on Tuesday, Some Put options Surges 52%

    On December 9, Eastern Time, Capricor Therap options saw a total of 136986 contracts traded, with calls accounting for 36% and puts making up 6%.

    LB Option·
    US
    CAPR
    -4.27%
    LB Option·
    US
    CAPR
    -4.27%

    Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR

    Kennedy Capital Management LLC reduced its stake in Capricor Therapeutics by 51.1% in Q2. Despite this, other institutional investors increased their positions. Analysts have mixed ratings, with a consensus price target of $34.50. Capricor's stock opened at $28.56, with a market cap of $1.31 billion. The company focuses on biological therapeutics for rare disorders, with CAP-1002 in clinical development for Duchenne muscular dystrophy.

    Market Beat·
    US
    CAPR
    -4.27%
    Market Beat·
    US
    CAPR
    -4.27%

    Capricor Therapeutics shares are trading higher after Oppenheimer raised the price target from $22 to $54.

    benzinga_article·
    US
    CAPR
    -4.27%
    benzinga_article·
    US
    CAPR
    -4.27%

    Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes

    Martin Shkreli's short position against Capricor Therapeutics Inc. is failing as the stock soared 440% following positive phase-3 trial results for its HOPE-3 cell therapy. The stock's Momentum score spiked from 3.83 to 96.4, indicating increased volatility and share price. Shkreli criticized the data, accusing the CEO of misrepresenting results. The stock's favorable price trend continues across short, medium, and long terms.

    fidelity·
    US
    CAPR
    -4.27%
    fidelity·
    US
    CAPR
    -4.27%
    Posts
    View More

    some green premarket movers $Q/C Tech(QCLS.US) $Rubrik(RBRK.US) $Lion(LGHL.US) $Victorias Secret(VSCO.US) $Cooper Cos(COO.US) $TTTAN $ChargePoint(CHPT.US) $Unity Software(U.US)lta Beauty(ULTA.US) $Int...........................

    © 2025 Longbridge｜Disclaimer